nc410 and pembrolizumab in mss/msi-l colorectal (crc) and ovarian cancer
Published 5 months ago • 67 plays • Length 2:08Download video MP4
Download video MP3
Similar videos
-
3:29
lenvatinib and pembrolizumab in microsatellite stable crc
-
9:02
pembrolizumab in msi-h crc tumors
-
9:25
debate: msi high colon cancer - immunotherapy
-
1:38
immuno-oncology in msi colorectal cancer
-
2:11
pembrolizumab vs. chemo in first-line mcrc
-
2:56
keynote-177: final pfs analysis of pembrolizumab in patients with msi-h/dmmr mcrc
-
4:56
asco: pembrolizumab vs. chemotherapy for msi-h metastatic colorectal cancer
-
1:08
first-line durvalumab monalizumab in microsatellite-stable crc
-
1:27
msi as a key immunotherapy biomarker in colon cancer
-
4:00
immunotherapy combinations in msi and mss mcrc
-
0:36
discover the link between msi instability and immunotherapy in cancer treatment 🔬🎗️
-
4:12
nondriver nsclc: adding pembrolizumab to platinum-based chemotherapy
-
1:20
dr. saab on immunotherapy in msi-h gi malignancies
-
1:07
what is microsatellite instability or msi?
-
1:28
dr. bekaii-saab on the response rate of pembrolizumab in msi-h crc
-
5:20
pembrolizumab improves on chemo in msi-h/dmmr mcrc
-
2:03
pembrolizumab therapy for microsatellite instability-high colorectal cancer
-
0:35
immunotherapy for msi high colon cancer
-
9:24
msi status and immunotherapy in advanced colorectal cancer